Pulsed Field Ablation Innovator Argá Medtech Announces €54 Million Oversubscribed Series B Capital Raise

Feb 27, 2024•almost 2 years ago

Amount Raised

€54 Million

Round Type

series b

EpalingesManufacturingMedical DeviceBiotechnologyHealth Care

Investors

Undisclosed Strategic InvestorGilde Healthcare (The Netherlands)Earlybird Health (Germany)Advent Life Sciences (Uk)

Description

Argá Medtech announced the closure of a €54M oversubscribed Series B funding. The financing enables Argá Medtech to advance the development of its innovative CSE™ Pulsed Field Ablation (PFA) system for treating AF through the execution of an IDE study in the US and a CE Mark study in the EU.

Company Information

Company

Argá Medtech

Location

Epalinges, Vaud, Switzerland

About

Argá Medtech is a private company developing Coherent Sine-Burst Electroporation™ (CSE™), a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF). The company is setting the standard for the next-generation Pulsed Field Ablation (PFA) systems with its versatile catheter design able to create circular, linear, and focal lesions, coupled with a unique CSE™ PFA waveform that allows energy titration based on tissue depth to achieve durable lesions.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends